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Abstract 
IMMUNOLOGICAL EFFECTS OF MORINGA OLEIFERA ON MALARIA AND 
MALNUTRITION DURING PLASMODIUM CHABAUDI INFECTION 
Jennifer Pilotos 
B.S., Appalachian State University 
M.S., Appalachian State University  
 
 
Chairperson: Dr. Michael M. Opata 
 
 
Malaria is a worldwide problem that affects millions of people yearly, especially in 
rural areas where life-saving anti-malarial drugs are not easily accessible. Residents in such 
rural areas also suffer from malnutrition due to limited supply of varieties of nutritious 
foods, thus they use herbal plants for both the treatment of various diseases and as 
nutritional supplements. One such herbal treatment, that also serves as a nutritional 
supplement, is Moringa oleifera. Both malaria and malnutrition are believed to be the 
associative cause of about half of the deaths in the world and children are most affected, 
suffering the greatest morbidity and death. As Moringa is used as a treatment regimen in 
malaria endemic areas, studies to determine its immunological effects on the infection are 
limited. Therefore, we hypothesized that in addition to suppression of parasite as reported 
by other investigators, Moringa treatment increases T helper 1 immunity in response to 
malaria infection. 
 Using a rodent parasite strain, Plasmodium chabaudi that mimics disease 
manifestations of the most virulent strain of human malaria, Plasmodium falciparum, we 
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observed that Moringa treatment reduced parasite burden compared to the untreated 
controls. Interestingly, mice treated with high dose Moringa (60 mg/mouse) for a short 
time (7 days) or low dose Moringa (30 mg/mouse) for a longer time (3 weeks), exhibited 
increased numbers of effector CD4+ T cells accompanied by an increase in Tbet expression. 
To further investigate this, we treated mice with Moringa after infection (curatively) or 
before infection (prophylactically) and observed that mice that were treated with Moringa 
after infection exhibited increased IFN and TNF secretion. Surprisingly, the mice that 
were treated before infection had significantly higher Tbet expression. These data suggest 
that Moringa treatment leads to CD4+ T cell activation and production of pro-inflammatory 
cytokines after malaria infection.  
To determine the contribution of Moringa on malnourished malaria infected mice, 
we induced malnutrition by limiting access to food to only 4 hours a day for 4 weeks, while 
control mice had unlimited access to mouse lab chow. We observed reduced numbers of 
CD4+ T cells, TNF proportions, and significantly greater Tbet expression in the food 
limited group compared to controls. Supplementation with Moringa in the limited group 
slightly restored CD4+ T cell activation, IL-2, and IL-10 production. Taken together, our 
results suggest that Moringa may be immunologically useful in the treatment of malaria 
and malnutrition. 
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Chapter 1 
INTRODUCTION 
 
Malaria is a life-threatening parasitic infection that is caused by four different 
strains of the Plasmodium parasite and impacts millions of people yearly. In 2017 there 
were 219 million cases of malaria which resulted in 435,000 deaths [1]. Of the four 
Plasmodium parasite strains, Plasmodium falciparum (P. falciparum) is the most deadly, 
accounting for almost all of the malaria-related deaths in Sub-Saharan Africa [2].  
In P. falciparum infection, the parasite goes through 3 phases and involves 2 hosts. 
The life cycle begins when the female Anopheles mosquito takes a blood meal and 
inoculates Plasmodium sporozoites into the mammalian host [3]. These sporozoites will 
migrate to the liver where they undergo asexual reproduction infecting hepatocytes to form 
schizonts; a process known as exo-erythrocytic schizogony (liver phase) [4]. This phase is 
largely asymptomatic and lasts approximately 7-10 days after which the schizont ruptures 
releasing merozoites into the bloodstream. This is known as the erythrocytic schizogony 
(blood phase) of malaria infection. The merozoites infect red blood cells and mature into 
trophozoites, eventually lysing the red blood cells and releasing up to 32 progeny [5]. 
During this blood phase, clinical symptoms of malaria infection which include fever, 
headache, chills, vomiting, anemia, and eventually enlargement of the spleen 
(splenomegaly) are observed [1]. Also, during this phase gametocytes are produced, which 
can be ingested by other mosquito vectors when they take a blood meal. Once in the 
mosquito’s stomach, the parasite’s sexual life cycle (sporogonic cycle) begins [3] and 
parasite zygotes are generated. These zygotes become motile and elongated, now called 
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ookinetes. The ookinetes migrate from the stomach to the midgut of the mosquito where 
they develop into oocysts which later mature into sporozoites [6]. These sporozoites 
migrate to the mosquito’s salivary glands and can be inoculated into another host when the 
mosquito takes a blood meal [7]. 
Unlike other Plasmodium strains, P. falciparum, causes chronic infection where 
parasite is often present in the blood 50 to 500 days post infection [8]. The host immune 
response is characterized by a robust T helper 1 (Th1) induced inflammatory response [9]. 
During the blood stage, merozoites lyse a large number of red blood cells which releases 
antigens into the bloodstream. These antigens activate resident macrophages and 
circulating monocytes which phagocytize the free merozoites and present them to CD4+ T 
cells in the spleen. The naïve T cells are then polarized and express transcriptional regulator 
Tbet leading to their differentiation into Plasmodium specific Th1 cells [10]. The 
proliferation and accumulation of these immune cells within the spleen causes the 
splenomegaly observed in malaria infection. These Plasmodium specific Th1 cells 
differentiate into effector and memory cells. Effector CD4+ T cells exit the spleen and enter 
the bloodstream where they produce large amounts of pro-inflammatory cytokines: TNF,  
IFN IL-12, and IL-18 [4]. These pro-inflammatory cytokines induce systemic 
inflammation and aid in the activation and recruitment of macrophages, B cells, and 
cytotoxic CD8+ T cells [11,12]. IFN and TNF most notably, help to boost cell mediated 
immunity as well as humoral immunity by inducing more monocyte/ macrophage 
activation and isotype switching in B cells [13]. The B cells produce parasite specific 
antibodies which assist in neutralization and opsonization of the parasite as well as tagging 
it for destruction by the complement system [14]. This immune response is unique to 
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malaria as most parasitic infections such as helminth infections are heavily reliant on early 
eosinophilic action and are largely T helper 2 (Th2) mediated [15]. P. falciparum is capable 
of suppressing eosinophilia [16] and Th1 mediated systemic inflammation is necessary in 
early blood phase to generate protective immunity and promote parasite clearance. Th2 
responses are necessary to protect against tissue damage due to inflammation, but these 
occur later in infection [17]. Therefore, the outcome of the infection is heavily reliant on 
proper timing of these responses by the adaptive branch of the immune system to not only 
control the infection but to generate protective immunity [9,18].  
 Naturally acquired protective immunity to malaria has been the topic of research 
for many years, as it is not generated quickly and requires chronic, repeat infections [9]. 
An individual will usually be infected before the age of 5 and develop severe malaria 
leading to complications such as severe anemia, respiratory distress in relation to metabolic 
acidosis [1], cerebral malaria [19], and acute kidney injury (AKI) [20]. These symptoms 
are life-threatening, but can easily be alleviated using anti-malarial drugs which clear the 
parasite by targeting the various life-cycle stages of the Plasmodium parasite as well as 
activating the immune response to control and eliminate the parasite [21,22]. Upon repeat 
exposure to the parasite, an individual will only develop mild and eventually asymptomatic 
malaria [23], but without chronic exposure these protective memory CD4+ T cell 
populations wane over time [24]. This slow development of immunity makes it difficult to 
develop efficient vaccines against malaria.  
To enhance immunity to malaria and reduce mortality rates, there are 2 current 
vaccine candidates in advanced clinical trials, the RTS,S/AS01 and the PfSPZ 
(Plasmodium falciparum sporozoite vaccine). Both are pre-erythrocytic vaccines aimed at 
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inducing cell mediated and humoral responses to malaria antigens [25,26]. The 
RTS,S/AS01 is a recombinant protein vaccine that co-expresses the P. falciparum 
circumsporozoite protein (CSP) sequence on the hepatitis B surface antigen. CSP mediates 
the transition between mosquito midgut and mammalian host hepatocyte. Therefore, the 
vaccine induces anti-CSP CD4+ T cells and antibodies  which provides protection, with or 
without vaccine boosters [27]. The RTS,S/AS01 has been shown to possess a 35.9% 
efficacy for the first year post vaccination but this decreased by 2.5% in the fourth year and 
4.4% in the seventh year post-vaccination [27].  The PfSPZ vaccine candidate is an 
attenuated sporozoite vaccine that is administered three times over 8-week intervals at a 
dose of 9.0x105 P. falciparum sporozoites. Clinical trials have shown that 64% of 
vaccinated volunteers exposed to controlled human malaria infection (CHMI) remained 
without parasitemia compared to the unvaccinated controls who all exhibited parasitemia 
post exposure. Of this vaccinated cohort six underwent repeat CHMI at 33 weeks after final 
immunization; 83% remained free of parasitemia [28]. This indicates that booster 
vaccination may enhance protection against the parasite.  
 The PfSPZ has demonstrated long-term protection in controlled human malaria 
against a variety of strains of Plasmodium by inducing Plasmodium specific CD4+ and 
CD8+ T cells. Despite these results these vaccine candidates are not yet on the market so 
the current treatment for malaria is by anti-malarial drugs. But drug resistance has been 
frequently noted in most of the commonly used anti-malarial drugs including chloroquine, 
sulphadoxine-pyrimethamine, quinine, piperaquine and mefloquine [29]. To combat 
development of drug resistance, combination therapies of anti-malarial drugs with 
artemisinin are being used [30]. Although these combination therapies have allowed for 
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treatment of these resistant strains, recent epidemiological studies have shown the 
emergence of artemisinin-resistant P. falciparum in Thailand, Laos, and Cambodia [31]. 
This growing resistance calls for the development of effective anti-malarial therapies and 
Moringa oleifera is a promising candidate [32]. 
Moringa oleifera, known as drumstick tree, is an edible plant from the Moringaceae 
species cultivated in many parts of the world, including sub-Himalayan tracts of India, 
Pakistan, Bangladesh, Afghanistan [33] and many parts of Africa [34]. It’s a perennial, 
pan-tropical tree characterized by fast growth, drought resistance, and a deciduous nature. 
It can be eaten raw, cooked, or dried [35] and has been used for centuries to prevent and/or 
treat a variety of disease in many rural malaria-endemic areas where access to conventional 
treatment is limited [36,37]. Several researchers have shown that Moringa possess many 
medicinal properties including: antimicrobial [37-43], anticancer [44], antioxidant [45-47], 
and anti-plasmodial [30,32,40,48,49]. Traditionally, this herbal tree is used to treat scurvy, 
purgation, headaches, fevers, otitis, sore throat, bronchitis, eye infections [40], STDs/STIs 
[41], and malaria [34,50].  
Studies performed to determine the anti-plasmodial effect of Moringa showed that 
it possesses potent suppressive and curative properties in Plasmodium infections. A dose 
dependent suppression of parasite growth up to 90% and an 80% reduction in parasite 
burden was observed [32]. Using both crude ethanolic and n-hexane Moringa leaf extracts, 
other investigators showed that the crude ethanolic extract inhibits parasitemia by 74.7-
95.6% and n-hexane extract inhibited by 59.3-87.9% [48]. Moringa has also been found to 
be effective in combination therapies with artesunate. In one study, a dose dependent 
suppression of parasitemia up to 91% was observed when Moringa is combined with 
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artesunate, compared to 50% with artesunate alone [30].  On the immune response, a study 
by Sijabat, and colleagues showed that a combination therapy of methanolic Moringa 
extract and artemisinin not only reduced parasite burden but increased the percentage of 
CD4+ T cells in a dose dependent manner [49]. These studies demonstrate that Moringa 
could be beneficial by inhibiting the parasite directly or activating immune CD4+ T 
lymphocytes.  
In other studies to determine the biochemical compounds with medicinal properties 
in Moringa, it was reported that Moringa is a rich source of vitamins, essential amino acids, 
carotenoids, polyphenols, phenolic acids, and flavonoids [37,42,43]. Many of these 
components are responsible for the plant’s medicinal and nutritional attributes. Anti-
parasitic effects of Moringa and other plants have been shown to be a result of a variety 
of chemical compounds concentrated within the leaves, gum, and flowers [51-53]. These 
compounds include saponins, isothiocyanates, tannins, phenolic compounds, and 
isoflavones [54,55]. Saponins have been shown to cause permeation of the cell membrane 
of parasites and induce vacuolization and disintegration of teguments. Isothiocyantes, 
such as 4-[(α-L-rhamnosyloxy) benzyl] isothiocyanate [56] found in Moringa, inhibit 
energy metabolism which interferes with the motor activity of parasites [54]. Tannins 
and phenolic compounds uncouple oxidative phosphorylation which inhibits energy 
generation as well as binds the glycoproteins on cuticles of worms and cause death. 
Lastly, isoflavaones inhibit enzymes of glycolysis and glycogenolysis, interrupt calcium 
balance, and negatively impact parasitic nitric oxide activity [54].  
In addition to its medicinal activity, Moringa is also been consumed widely as a 
nutritional supplement in many malaria endemic areas that are effected by malnutrition 
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[57]. Malnutrition is the implicated with approximately half of the deaths reported in 
children under the age of five in many countries [58]. The effect of malnutrition on malaria 
has been the topic of much controversy over the years as some studies suggest that 
malnutrition exacerbates the already life-threating symptoms of malaria infection, leading 
to greater malaria morbidity and mortality [59], while others suggest that malnutrition 
reduces parasitemia, leading to less disease severity [60,61]. Studies have shown that 
undernourished and stunted children [62] were more susceptible to malaria infection 
because of a notable reduction in T lymphocytes, impaired antibody production, decreased 
complement production, and atrophy of the thymus and other lymphoid tissues [63]. This 
was backed up by another study comparing malnourished, stunted, and wasted children 
[61]. In their report, the investigators showed that malnourished and stunted children had 
reduced anti-P. falciparum IgG antibodies [64]. Another study to determine the effect of 
protein energy malnutrition found that controlled trials of vitamin A and zinc 
supplementation led to significant reduction in clinical malaria attacks [59]. Thus, 
malnutrition has a direct link with malaria immunity and/or severity. 
To combat malnutrition, individuals consume Moringa for its vitamins, minerals, 
and protein content [65]. The leaves and seeds can be eaten green, roasted, seeped for teas, 
as well as dried and ground into a powder- commonly added to curries. Moringa is thought 
to be a high source of fiber, protein, calcium, iron, vitamin C, and carotenoids [33]. 
Specifically, Moringa provides more than 7 times the amount of Vitamin C in oranges, 10 
times the amount of Vitamin A in milk, 9 times the amount of protein in yogurt, 15 times 
the amount of potassium found in bananas, and 25 times the amount of iron in spinach [66]. 
Studies have also shown that 8 grams of Moringa leaf powder can provide a toddler with 
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14% of the protein, 23% of the iron, and 40% of the calcium recommended daily [35]. 
Studies in a cohort of malnourished children in rural India found that Moringa improved 
protein energy malnutrition in 70% of grade II malnourished children and 60% of grade I 
malnourished children [67].  The growing resistance to anti-malarial drugs as well as the 
nutritional and medicinal properties observed by different researchers make Moringa a 
promising candidate in both malnutrition and malaria infection.   
Therefore, the first aim of our study was to assess the effect of Moringa on P. 
chabaudi parasite burden and malaria immunity. We hypothesized that Moringa would 
decrease parasite burden and increase the number of activated CD4+ T cells and cytokine 
secretion. Given that malnutrition is common in many rural malaria endemic areas our 
second aim was to assess the effect of food limitation induced malnutrition on malaria 
immunity and determine if Moringa can be used as a supplement to remediate malnutrition 
and improve immune response. We hypothesized that food limitation would decrease the 
number of activated CD4+ T cells and impair cytokine secretion, but Moringa would 
remediate these detrimental effects by increasing the number of activated CD4+ T cells and 
cytokine secretion.  
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Chapter 2 
MATERIALS AND METHODS 
2.1 Mice and parasite 
C57BL/6 mice were obtained from Harlan labs and breeding colonies were 
maintained at the Appalachian State University animal facility under a 12:12 light/dark 
cycle. All mice were cared for under the guidelines set by the IACUC (protocol 17-04).  
The rodent strain of malaria Plasmodium chabaudi AS (P. chabaudi), an 
established mouse model for human malaria, was used in this study to mimic the chronic 
nature of the human parasite strain P. falciparum. The parasite was a kind gift from Dr. 
Robin Stephens at the University of Texas Medical Branch, with permission from Dr. Jean 
Langhorn (Francis and Crick Institute, UK). 
 2.2 Preparation of Moringa pellets and Moringa extract 
Moringa leaves and extract were a kind gift from Dr. Chishimba Nathan Mowa in 
the Department of Biology at Appalachian State University, or obtained from Natural 
Market (Boone, NC). Otto’s cassava flour was obtained from Earth Fare natural market 
(Boone, NC). Cassava flour was used in this study to make Moringa pellets as it makes a 
good binding agent and contains empty calories. Three doses of Moringa pellets were 
utilized in this study: low, high, and food limitation nutritional dose (see dosages below). 
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a) Extract  
  The extract was prepared by extracting Moringa leaves into 100% ethanol and 
ethanol was evaporated off utilizing a rotary evaporator and resuspended in DI water at a 
concentration of 1.00g/mL. 
b) Low dose Moringa pellets 
Moringa pellets were made every 3 days using 10.10g of cassava flour and 30mg 
of Moringa leaf powder per mouse under a sterile hood. These were mixed with sterile DI 
water to form pellets and ~2g peanut butter mixed in for flavor enhancement. The control 
pellets were made using 10.40mg of cassava flour and ~2 g of peanut butter. Six pellets 
were made formed for both groups and allowed to air dry. Mice were given two pellets 
daily along with standard mouse chow for 3 days and another batch was made fresh.  
c) High dose Moringa pellets 
Moringa pellets were made every 3 days using 10.10g of cassava flour and 60mg 
of Moringa leaf powder per mouse under a sterile hood. These were mixed with sterile DI 
water to form pellets and ~2g of peanut butter mixed in for flavor enhancement. The control 
pellets were made using 10.70g of cassava flour and ~2 g of peanut butter. Six pellets were 
formed for both groups and allowed to air dry. Mice were given two pellets daily along 
with standard mouse chow for 3 days and another batch was made fresh.  
d) Food limitation nutritional dose Moringa pellets  
Moringa pellets were made every 3 days using 20.10g of cassava flour and 500mg 
of Moringa leaf powder per mouse under a sterile hood. These were mixed with sterile DI 
11 
 
 
water to form pellets and ~4g of peanut butter mixed in for flavor enhancement. Twelve 
pellets were formed and allowed to air dry. Mice were given four pellets daily along with 
standard mouse chow for 3 days and another batch was made fresh.  
2.3 Treatment of mice 
a) Moringa experiments 
Adult female C57BL/6 mice were utilized in these experiments to determine the effect of 
Moringa on generation of malaria immunity. Mice were fed Moringa pellets daily for 7 or 
23 days before infection (pre-infection) or after infection (post-infection). Control mice 
were fed control pellets for 7 days. In prophylactic/curative studies mice were fed for 3 
weeks before and throughout infection (prophylactic) or 9 days after infection (curative). 
Mice were infected with a 1x105 dosage of P.chabaudi AS and sacrificed at day 9 post-
infection (p.i) to harvest spleen for effector time points or day 60 (p.i.) for memory time 
points.  
 
 
 
 
 
 
Figure 1: Schematic for Moringa treatment timeframes. Mice were treated for either short term (7 days), 
long term (3 weeks), prophylactically (3 weeks and continuous feeding until sacrifice), or curatively (9 days). 
Mice were sacrificed at either 9 days post infection (p.i), 23 days p.i., or 60 days p.i. depending on the 
populations that were studied.   
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b) Food limitation experiments  
Adult and young C57BL/6 mice were utilized in these experiments to determine the 
effect of food limitation induced malnutrition on malaria immunity. Young mice were 
weaned at 3 weeks and food limitation began when mice reached a body weight of 10-12g. 
Food limitation was performed by only allowing the “limited group” of mice to access to 
standard lab mouse chow for 4 hours daily while controls were given unlimited access 24/7. 
Mice were weighed every other day or weekly and infected with a 1x105 dosage of 
P.chabaudi AS. Experimental mice were sacrificed at day 9 or day 60 (p.i) to determine 
immune response in spleen cells. 
c) Food limitation and Moringa experiments 
Adult C57BL/6 mice were utilized in these experiments to determine if Moringa could 
remediate the effects of food limitation induced malnutrition on malaria immunity. Food 
limitation was performed by only allowing limited groups access to standard mouse chow 
for 4 hours daily while controls were given unlimited access 24/7. A third group of the 
food limited mice were supplemented with Moringa pellets as a nutritional supplement 
after food was removed. All mice were weighed every other day or weekly and infected 
with a 1x105 dosage of P.chabaudi AS and sacrificed at day 9 p.i. to determine immune 
response in spleen cells. 
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2.4 Determining Parasitemia  
Parasite burden was determined using thin blood smears obtained by bleeding the 
tail of the mice at days 3, 5, 7, 8, and 9 post infection with P.chabaudi AS. The slides were 
stained with Diff-Quik and parasites were counted by microscopy in 10 to 50 different 
fields depending on the parasite load and day of infection. To determine percent 
parasitemia, the number of infected red blood cells was divided by the total number of red 
blood cells and multiplied by the counted fields. The outcome was multiplied by 100 as 
shown in the formula below.  
%𝑃𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑚𝑖𝑎 =
𝑖𝑅𝐵𝐶
(𝑇𝑜𝑡𝑎𝑙 𝑅𝐵𝐶)
 * cells counted *100  
Cells counted= (total RBC* fields) 
2.5 Flow cytometry analysis  
Mouse spleens were collected in ISCOVEs media and mashed through mesh 
screens to obtain a single cell suspension. Cells were incubated with red blood cell (RBC) 
lysis buffer to lyse red blood cells which was stopped by adding media. The cells were then 
resuspended in complete ISCOVEs media. The cells were counted using a hemocytometer 
and an aliquot was taken for staining for extracellular molecules using fluorochromes 
FITC, PE, and PE-Cy5, and PE-Cy7 to determine T cell activation. For intracellular 
cytokine staining, an aliquot from the counted cells were stimulated in vitro with a cell 
stimulation cocktail (Tonbo Biosciences, San Diego, CA) for 5 hours. After 5 hours of 
stimulation, cells were stained with CD4 FITC and incubated for 40 minutes in the fridge 
before fixation with 2% Paraformaldehyde. Cells were then permeabilized using 
14 
 
 
perm/wash buffer (Tonbo Biosciences, San Diego, CA), and stained with IFN PE, TNF 
PE-Cy7, IL-2 PE, and IL-10 FITC (all from Biolegend, San Diego, CA). Data was collected 
on an FC500 (Beckman Coulter, Indianapolis, IN) and analyzed by FlowJo (Ashland, OR).   
2.6 Data Analysis   
All flow cytometry data were analyzed using the FlowJo software (Ashland, OR). 
The number of cells was determined by the counts taken using the hemocytometer. We 
determined the average and standard error of the mean for all groups using Microsoft excel 
number of cells. We ran Student’s two-tailed t tests and generated graphs using the Prism 
GraphPad 5 software (La Jolla, CA).  
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Chapter 3 
RESULTS 
3.1 Moringa Experiments 
Moringa Treatment Reduces Parasitemia  
Given that Moringa possesses anti-plasmodial properties, we sought to determine 
the effect of Moringa extract and Moringa pellets on parasite burden in infected mice. To 
do this, we fed Moringa pellets (Figure 2a) or extract (via oral gavage) (Figure 2b) along 
with their standard mouse chow. We gave Moringa to the mice for 7 days before (pre) or 
7 days after (post) infection with P. chabaudi AS. We took blood smears by tail bleeds at 
days 3, 5, 7, and 8 to determine parasitemia by microscopy. Consistent with literature we 
observed lower parasite burden in Moringa treated groups, but this was not significantly 
different from the control mice (Figure 2). This data indicates that Moringa treatment with 
solid pellets or ethanolic extract have an inhibitory effect on parasitemia. As there was no 
difference in the 2 methods of moringa administration, the rest of the experiments were 
done with moringa pellets. 
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Figure 2: Moringa treatment decrease parasitemia. C57BL/6 mice were fed (a) Moringa leaf pellets or 
(b) Moringa leaf ethanolic extract for 7 days pre-infection or post infection; control mice were fed peanut 
butter control pellets. All groups were infected with a 1x105 infected red blood cells (iRBCs) of P.chabaudi 
AS. Graphs show average parasitemia of 3-4 mice per group from two similar experiments. Error bars 
represent SEM and no significant difference was observed between groups. Significance was determined by 
two-tailed t test with 95% confidence and p values of >0.05. Pre = Moringa treatment before infection, Post 
= Moringa treatment after infection, Cnt = Control with no Moringa treatment. 
 
Short term treatment with Moringa pellets post-infection leads to decreased effector 
CD4+ T cell numbers. 
Since Moringa is used for many ailments and our results showed reduced 
parasitemia in Moringa treated mice, we wondered if Moringa treatment had an effect on 
immune response. We fed Moringa pellets to the mice for 7 days pre or post infection with 
P. chabaudi. We then sacrificed all mice at day 9 post infection to determine the 
percentages and numbers of effector CD4+ T cells, B cells, and cytokine secretion. We 
observed no differences in B cell activation between the groups, (data not shown), but there 
was a significant reduction in the number of effector CD4+ T cells in mice treated post-
infection with Moringa pellets (Figure 3a). We did not observe significant differences in 
the percentage or number of pro-inflammatory cytokines IFN and TNF between the 
groups (Figure 3b&c). 
Figure 3: Number of effector T cells are reduced in mice fed on Moringa pellets after infection. 
C57BL/6 mice fed low dose Moringa pellets for 7 days pre or post-infection with 1x105 dose of P. chabaudi 
AS and control mice were given control pellets prior to infection. Graphs show (a) effector T cells identified 
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using CD4+CD44hiCD62Llo, (b) IFN and (c) TNF producing CD4
+
 T cells determined using intracellular 
cytokine stimulation assay and analyzed using flow cytometry.Data represent 4 mice per groups from 2 
independent experiments. Error bars represent SEM and significance was determined by two-tailed t test with 
95% confidence, *p<0.05. Pre = Moringa treatment before infection, Post = Moringa treatment after 
infection, Cnt = Control with no Moringa treatment. 
 
High dose Moringa treatment increased IFN and Tbet expression in pre-infection 
treated Mice  
Given that individuals in developing nations consistently take Moringa, it is likely 
that they consume it at a higher dose than the recommended 100g as a nutritive supplement 
for humans [57]. Therefore, since we observed a reduction in activated effector CD4+ T 
cells in post-treated mice with the low dose Moringa treatment, we were interested in 
determining the effect of a higher dose of this treatment on the activation of CD4+ T cells. 
Mice were given high dose Moringa pellets-60mg per mouse (2-fold increase) per day for 
7 days pre or post infection with appropriate controls. The mice were sacrificed on day 9 
post infection and percentage and numbers of effector CD4+ T cells were evaluated, as well 
as pro-inflammatory cytokines (IFN & TNF) and Tbet. We did not observe a significant 
difference in parasitemia and T cell numbers (Figure 4a&b). Interestingly, there was a 
significant decrease in the proportion of IFN production in the post-treated mice (Fig 
4c&d). Production of IFN and TNF is associated with increased expression of Tbet, a 
master regulator of CD4+ T helper 1 (Th1) subset [68]. Therefore, we determined the effect 
of high dose Moringa treatment on Tbet. We observed an increase in both the percentage 
(Figure 4g) and number (Figure 4h) of CD4+ T cells expressing Tbet in the mice that were 
given Moringa before infection.   
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Figure 4. Tbet expression is increased in mice fed high dose Moringa before infection. Mice were fed 
high dose Moringa pellets (60mg/mouse) for 7 days pre-infection or post infection, including respective 
controls without Moringa treatment. Mice were infected with a 1x105 dose of P. chabaudi AS, and sacrificed 
at day 9 post-infection. Graphs show (a) Percent and (b) number of activated effector CD4+ T cells are 
identified as CD4+CD44hiCD62Llo, (c,e) Percent and (d,f) number of IFN and TNF producing CD4
+
 T 
cells determined using intracellular cytokine staining and analyzed using flow cytometry. (g) Percent and (h) 
number of Tbet expression on CD4
+
 T cells determined using flow cytometry. 
19 
 
 
 
Long-term treatment with Moringa pellets post-infection leads to increased numbers of 
effector and TNF producing CD4+ T cells  
As most people in malaria endemic areas consistently consume Moringa for a 
longer time and given the reduction in cytokine production that we observed in short term 
post-infection treated mice (Figure 3), we wondered if long term Moringa treatment would 
affect the immune response more. To accomplish this, we fed Moringa to the mice for 3 
weeks pre or post infection with P. chabaudi with appropriate controls that were only fed 
normal lab chow.  We then sacrificed the mice after a total of 6 weeks and determined the 
percentages and number of effector CD4+ T cells and pro-inflammatory cytokine secretion. 
Interestingly, when Moringa was given for a long duration (3 weeks), we observed an 
increase in the number of effector CD4+ T cells in mice treated post infection compared to 
the pre-infection treated mice and the control groups, but no significant difference in the 
percentages of these cells (Figure 5a&b). We also observed an increase in TNF secretion, 
but no statistical difference in IFN secretion (Figure 5c&d) between groups. 
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Figure 5: Long-term treatment with Moringa pellets increases the number of activated effector and TNF 
secretion in post infection treated mice. C57BL/6 mice were fed for 3 weeks pre-infection or post infection; 
control mice were fed control pellets. Mice were infected with a 1x105 P. chabaudi AS. Mice were sacrificed 
6 weeks later at day 23 post infection. (a) Percent and (b) number of activated effector CD4
+
 T cells identified 
using CD4+CD44hiCD62Llo and analyzed by flow cytometry. Percentage of CD4
+
 T cells producing (c) IFN 
and (d) TNF respectively. Data represent 3 mice/group. Error bars represent SEM and significance was 
determined by two-tailed t test with 95% confidence, *p<0.05. Pre = Moringa treatment before infection, 
Post = Moringa treatment after infection, Cnt = Control with no Moringa treatment. 
 
Low dose prophylactic or curative consumption of Moringa leads to increased CD4+ T 
cell activation and pro-inflammatory cytokine secretion.  
Traditionally individuals who consume Moringa for its anti-plasmodial properties 
consume it either before being sick as a prophylactic or after getting sick for cure 
(curatively) [50]. To better mimic these conditions, we fed mice a lower dose of Moringa 
pellets prophylactically for 3 weeks prior to and throughout infection or curatively after 
infection with P. chabaudi. Blood smears were taken on day 9 before sacrifice to determine 
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parasite and we observed a significant decrease in parasite load in the Moringa treated mice 
compared to the untreated controls (Figure 6). Upon sacrifice, we determined the 
proportions and number of activated effector CD4+ T cells, cytokine production and Tbet 
expression. Consistent with lower parasitemia, we observed significantly higher numbers 
of activated CD4+ T cells in curative (post) treated group compared to controls. The 
prophylactically treated mice had a trend towards increased cell numbers but did not reach 
statistical difference (Figure 6b). We also observed higher proportions and number of 
CD4+ T cells secreting pro-inflammatory cytokines (IFN and TNF) in Moringa treated 
mice compared to control mice (Figure 6c&d). Strikingly, the prophylactic treated group 
had significantly higher proportions of Tbet expression (Figure 6e). Both groups of 
Moringa treated mice exhibited increased numbers of CD4+ T cells expressing Tbet 
compared to control mice (Figure 6f).  
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Figure 6: Prophylactic and curative treatment with Moringa increase the number of activated CD4
+
 
T cells, pro-inflammatory cytokines, and Tbet expression after malaria infection. Mice were fed low 
dose Moringa pellets prophylactically for 3 weeks prior to and throughout infection or curatively after 
infection with appropriate controls. All mice were infected with a 1x105 dose of P. chabaudi AS and sacrificed 
at day 9 post-infection. Summary graphs show (a) parasitemia at day 9 p.i, (b) effector CD4+ T cells identified 
as CD4+CD44hiCD62Llo, (c) numbers of IFN and (d) TNF production by CD4
+
 T cells determined using 
intracellular cytokine staining and analyzed using flow cytometry. (e) Proportions and (f) number of Tbet 
expression on CD4+ T cells was also determined using flow cytometry. Data represents an average of 5 mice 
per group and error bars represent SEM. Significance was determined by two-tailed t test with 95% 
confidence, *p<0.05. Pre = Prophylactic Moringa treatment before and throughout infection, Post = Curative 
Moringa treatment after infection, Cnt = Control with no Moringa treatment. 
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Long term prophylactic Moringa treatment lead to increased central memory CD4+ T 
cell proportions but reduced pro-inflammatory cytokine secretion 
Given the results observed in the low dose prophylactic versus curative effector 
populations observed above, we next investigated the effect of Moringa treatment on the 
generation of T effector memory (Tem) and T central memory (Tcm). These are especially 
important in malarial immunity as they are necessary to fight subsequent infections [24]. 
We accomplished this by feeding the mice low dose (30mg) or high dose (60mg) Moringa 
pellets prophylactically for 3 weeks prior to and throughout infection or curatively after 
infection. We sacrificed the mice at day 60 post infection with P. chabaudi to determine 
these memory populations. We observed a reduction in the proportions of Tem in post-
infection treated mice, but no difference in cell numbers (Figure 7a&b). We also observed 
an increase in the proportions of Tcm in the pre-treated mice, compared to post-treated and 
control groups (Figure 7c&d). There was an increase in IFN (Figure 7d), and slightly 
higher TNF (Figure 7e) in the mice fed Moringa after infection for cure compared to the 
prophylactic and control groups.  
 In the high dose we observed similar results, but the reduction in Tem proportion 
was observed in the prophylactically treated mice compared to the curatively fed mice and 
controls but no difference in the numbers (Figure 8a&b). Similar to the low dose we 
observed increased proportions of Tcm in the prophylactic compared to the curative and 
controls but no difference in numbers (Figure 8c&d). This was accompanied by an 
increase in Tbet expression in the prophylactic treated mice, but no statistical significance 
in cell numbers (Figure 8i&j). Surprisingly, pro-inflammatory cytokines were not 
statistically different but a trend towards increased IFN in curatively fed mice (Figure 
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8g&h). We decided to investigate IL-10 and IL-2 expression to determine if this could be 
due to anti-inflammatory cytokine IL-10 or a defect in IL-2.  
Interleukin 10 (IL-10) is an anti-inflammatory cytokine which is secreted during 
malaria infection to protect against tissue damage by systemic inflammation. Interleukin 2 
(IL-2) is an autocrine stimulatory cytokine produced by T cells upon interaction with 
antigen presenting cell (APC) such as a macrophage or dendritic cell [69]. This interleukin 
is necessary for the differentiation and proliferation of Plasmodium specific Teff cells. We 
observed increased IL-2 expression in prophylactic mice and a trend towards increased IL-
2 in curatively fed mice compared to controls. We observed similar trends in the IL-10 
production between the groups although there were no significant differences (Figure 8 
e&f). 
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Figure 7: Low dose curative treatment with Moringa decreased the number of activated Tmem 
proportions and pro-inflammatory cytokines in long term treatment. Mice were fed low dose Moringa 
pellets prophylactically for 3 weeks prior to and throughout infection or curatively after infection with 
appropriate controls. All mice were infected with a 1x105 dose of P. chabaudi AS and sacrificed at day 60 
post-infection. Summary graphs show (a) proportions and (b) numbers of effector memory CD4+ T (Tmem) 
cells identified as CD4+CD44hiCD62Llo, (c) proportions and (d) numbers of central memory CD4+ T (Tcm) 
cells (e) IFN and (f) TNF production by CD4+ T cells determined using intracellular cytokine staining and 
analyzed using flow cytometry. Data represents an average of 3 mice per group and error bars represent SEM. 
Significance was determined by two-tailed t test with 95% confidence, *p<0.05. Pre = Prophylactic Moringa 
treatment before and throughout infection, Post = Curative Moringa treatment after infection, Cnt = Control 
with no Moringa treatment. 
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Figure 8: High dose prophylactic and curative treatment with Moringa decreased Tmem proportions 
but increased Tbet and Il-2 expression in long term treamtent. Mice were fed low dose Moringa pellets 
prophylactically for 3 weeks prior to and throughout infection or curatively after infection with appropriate 
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controls. All mice were infected with a 1x105 dose of P. chabaudi AS and sacrificed at day 9 post-infection. 
Summary graphs show Tem (a) proportions and (b) numbers identified by CD4+CD44hiCD62Llo. Tcm (c) 
numbers and (d) proportions CD4+CD44hiCD62Lhi. Proportion of IL-2 (e), IL-10 (f), IFN (g), and TNF (h) 
production by CD4
+
 T cells determined using intracellular cytokine staining and analyzed using flow 
cytometry. (i) Proportions and (j) number of Tbet expression on CD4+ T cells was also determined using 
flow cytometry. Data represents an average of 5 mice per group and error bars represent SEM. Significance 
was determined by two-tailed t test with 95% confidence, *p<0.05. Pre = Prophylactic Moringa treatment 
before and throughout infection, Post = Curative Moringa treatment after infection, Cnt = Control with no 
Moringa treatment. 
 
3.2 Malnutrition Experiments  
Malnutrition induced Tbet expression but reduced effector CD4+ T cell activation 
Malnutrition is a common issue in many low income, malaria endemic areas and 
children are the most affected by malnutrition and malaria infection, as they comprise the 
highest number of deaths and morbidity observed in many malaria endemic areas 
[59,70,71]. To understand how malnutrition affects CD4+ T cell immunity against malaria 
infection, we developed a malnutrition model by food limitation. As malnourished people 
are exposed to a poor diet from childhood, we utilized 3-week-old mice that weighed 10-
13g and limited their access to standard lab mouse chow (4g per mouse) to 4 hours daily, 
while control mice had unlimited access. The mice were exposed to this pattern of feeding 
for 4 weeks to induce malnutrition, which was followed by infection with a 1x105 dose of 
P. chabaudi in the third week of limited food feeding. The mice were sacrificed at d9 post-
infection and CD4+ T cell, and cytokine secretion profiles were determined. We observed 
reduced percentages and numbers of effector CD4+ T cells in the malnourished group 
compared to control mice (Figure 9a&b). There was a slight reduction in TNF 
production but no difference in IFN (Figure 9c-f) . Surprisingly, these mice exhibited 
increased expression of Tbet compared to controls (Figure 9 &h).  
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Figure 9: Malnourished mice express high Tbet but reduced effector CD4+ T cells. Young mice (3 weeks 
old and 10-13g of body weight) were malnourished through food limited by only allowing mice access to 
food for 4 hours daily for 3 weeks, while controls had unlimited access to food. All mice were infected with 
a 1x105 dose of P. chabaudi AS and sacrificed at day 9 post-infection. Summary graphs show (a) percent and 
(b) numbers of effector CD4+ T cells identified as CD4+CD44hiCD62Llo. (c) Percent and (d) numbers of 
IFN (e) Percent (f) and numbers of TNF producing CD4+ T cells determined using intracellular cytokine 
staining. (g) Percent and (h) number of Tbet expression on CD4+ T cells was also determined using flow 
cytometry. Data represents an average of 5 mice per group and error bars represent SEM. Significance was 
determined by two-tailed t test with 95% confidence, *p<0.05. Lim = Malnourished and Con = Control 
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Malnutrition induced Tbet expression and reduced pro-inflammatory cytokine secretion 
by effector memory and central memory CD4+ T cells  
Since we observed reduced numbers of effector CD4+ T cells in the malnourished 
mice, we reasoned that this may affect the generation and survival of memory CD4+ T cells 
as seen in malaria infection. Therefore, we induced malnutrition in already adult mice by 
food limitation, as described above, with littermate controls having unlimited access. After 
4 weeks of inducing malnutrition, mice were infected with a 1x105 dose of P. chabaudi. 
The mice were kept on same pattern of feeding until d60 post-infection at which time they 
were sacrificed to determine effector (Tem) and central (Tcm) memory T cell proportions 
and numbers, cytokine secretion profiles, and Tbet expression. We observed no difference 
in the Tem or Tcm numbers (Figure 10a&b), but there was a slight reduction in the 
proportions of IL-2, and no difference in IL-10 in the malnourished group compared to 
controls (Figure 10c&d). Both IFN and TNF were reduced in the malnourished groups 
as well, although no statistical difference in IFN was observed (Figure 10e&f). Consistent 
with the effector time point, Tbet proportions and numbers were statistically higher in the 
malnourished group compared to the controls (Figure 10g&h). 
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Figure 10: Malnutrition did not affect memory T cells, but induced Tbet expression and decreased cytokine 
secretion. Adult mice (6 weeks) were malnourished by 4 hour food limitation daily for 4 weeks or controls 
given access to unlimited food supply. All mice were infected with a 1x105 dose of P. chabaudi AS and 
sacrificed at day 60 post-infection. Summary graphs show (a) numbers of Tem and (b) Tcm CD4+ T cells 
identified as CD4+CD44hiCD62Llo and CD4+CD44hiCD62Lhi, respectively. (c-f) Percent of IL-2, IL-10, IFN 
TNF producing CD4+ T cells determined by intracellular cytokine staining and analyzed using flow 
cytometry. (g) Percent and (h) number of Tbet expressing CD4+ T cells determined using flow cytometry. 
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Data represents an average of 6 mice per group and error bars represent SEM. Significance was determined 
by two-tailed t test with 95% confidence, *p<0.05. Mal = Malnourished and Cnt = Control. 
 
3.3 Malnutrition and Moringa 
Nutritional supplementation with Moringa increased CD4+ T cell activation in 
malnourished food limited mice 
The reduced numbers of effector CD4+ T cells in malnourished mice was expected, 
as studies suggest that malnutrition has detrimental effects on immune response [59,67]. 
Given that Moringa is rich in protein [57] and our results have shown it to increase CD4+ 
T cells numbers and proportions, we sought to determine if it could remediate the immune 
suppressive effects of malnutrition. Using the malnutrition model of 4 hours food 
restriction, we malnourished 2 sets of mice. One group of the malnourished mice was given 
nutritional Moringa pellets upon food removal for the remaining 20 hours. We observed 
that Moringa increased Teff proportions compared to limited mice, with trends towards 
increased cell numbers that did not reach statistical significance (Figure 11a&b). 
Surprisingly we did not observe increased IL-2 secretion in the Moringa supplemented 
mice, but did observed slightly increased IL-10 secretion (Figure 11c-f). IL-10 has been 
shown to be critical for regulating pathology in malaria infection. In regard to pro-
inflammatory cytokine secretion we observed reduced secretion of IFN in the Moringa 
supplemented mice compared to controls, but no difference in TNF. We also observed 
increased Tbet expression in the malnourished mice compared Moringa fed mice and 
controls (Figure 11i-j). Taken together these results suggest that Moringa supplementation 
may ameliorate some of the immune defects induced by malnutrition upon malaria 
infection.  
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Figure 11: Nutritional supplementation with Moringa increased Teff proportions in malnourished mice. 
Adult mice (6 weeks) were malnourished by food limitation by allowing mice access to food for 4 hours 
daily at for 4 weeks prior to infection. A second group of malnourished mice were supplemented with 
Moringa (500mg per mouse), while controls had constant supply of food. All mice were infected with a 1x105 
dose of P. chabaudi AS and sacrificed at day 9 post-infection. Summary graphs show Teff (a) Percent and 
(b) numbers of effector CD4+ T cells identified by CD4+CD44hiCD62Llo. (c-f) Percent and numbers of IL-2. 
and IL-10 producing CD4+ T cells. (g) Percent of IFN and TNF (h) producing CD4+ T cells determined 
using intracellular cytokine staining. (i) Proportions and (j) number of Tbet expression on CD4+ T cells was 
also determined using flow cytometry. Data represents an average of 5 mice per group and error bars represent 
SEM. Significance was determined by two-tailed t test with 95% confidence, *p<0.05. Mal = Malnourished 
and Cnt = Control. 
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Chapter 4 
DISCUSSION 
Drug resistance to malaria infections has been observed for years and combination 
therapies with artemisinin have become the normal course of treatment. Quinine and 
artemisinin combination therapies as well as other anti-malarial drugs are currently used to 
effectively treat malaria resistant strains of P. falciparum[29]. These drugs and adjuncts 
are plant derived; quinine is derived from the cinchona tree while artemisinin is derived 
from the sweet wormwood plant [72,73]. But despite their effectiveness, the investigation 
of other potential antimalarial drugs or adjuncts is greatly needed, as there are new cases 
of resistance reported to the combination therapies [74]. Therefore, low cost, effective anti-
malarial adjuncts will be needed to combat this growing resistance and Moringa is a good 
candidate as it is already widely used in southern Nigeria for its medicinal and nutritional 
properties [75]. Moringa is frequently consumed raw, as a vegetable, or added into various 
foods as a supplement [57]. It is also commonly boiled in water, to make an extract, and 
used to treat a variety of ailments including: malaria, stomach pains, high blood pressure, 
stroke, rheumatism, and to ease labor symptoms with a greater than 70% fidelity level [75]. 
Given that this plant is low cost, easy to grow, and is already commonly used to treat 
malaria [35,50], we investigated its potential to improve the immune response to P. 
chabaudi as well as remediate the detrimental effects of food limitation induced 
malnutrition, as studies on this topic are limited.   
In our current report we observed that when mice were given a low dose of Moringa 
for 3 weeks after infection, the number of activated CD4+ T cells in the spleens of the mice 
increased in response to the Plasmodium infection. This was accompanied by increased 
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proportions of TNF (Figure 5). When we treated the mice with a high dose for a short 
time, there was no effect on activated effector CD4+ T cells in the treated mice, but long-
term treatment increased CD4+ T cell activation and cytokine secretion capability. 
Surprisingly, while there were no significant variabilities in cell activation or cytokine 
secretion in the mice treated before infection with high dose pellets, Tbet expression was 
increased in the effector T cells.  Higher Tbet expression in this case promotes Th1 cytokine 
secretion, which could explain the similar proportions of cytokines secretion seen among 
the groups as seen by others [36]. In all cases, the treated mice consistently had reduced 
parasitemia. In some instances, we got a decrease in IFN secretion. In our case, we 
speculate that the timing and dose of treatment may influence the cytokine inhibition and 
stimulatory effects of Moringa.  
 Moringa has long been suggested to possess some anti-inflammatory properties 
[36] and murine studies using Moringa leaves have shown a significant reduction in 
experimentally induced inflammation [76,77]. The immune response to malaria is 
characterized by a robust Th1 induced inflammatory response [9]. This robust response is 
triggered by the expression of transcriptional regulator Tbet [10] which is upregulated 
when the T cells are primed to secrete IFN and other Th1 related cytokines. Unlike most 
parasitic infections, such as helminth, which rely on eosinophils, P. falciparum is capable 
of suppressing eosinophilia [16], and is characterized by secretion of IFN and TNF [4]. 
Recent studies have shown production of IL-10 by Th1 cells to regulate the inflammatory 
response [9]. In some cases, a surge in inflammation due to malaria infection leads to severe 
and moderate malaria, specifically higher levels of circulatory pro‐inflammatory cytokines, 
including TNFα and IL‐6 were indicators for severe malaria, but IL-10 regulates the 
36 
 
 
outcome [78]. As Moringa is reported to have anti-inflammatory effects [79], it could 
reduce this surge alleviating the effects that cause severe malaria. 
When we tested for curative or prophylactic treatment to mimic field scenarios 
where people take Moringa continuously, we observed that Moringa treatment inhibited 
parasitemia in both cases, whether administered for cure or for prophylaxis. This was 
accompanied by significant activation of CD4+ T cells, cytokine secretion and Tbet 
expression, a master regulator for Th1 CD4+ T cell subset. Consistently higher Tbet in pre-
infection treated mice indicates that early treatment with Moringa may program the cells 
to be more Th1 biased. 
Some of the discrepancies observed in our pre versus post-infection treatment in 
our study may be due to accumulation of macromolecules. A biochemical safety study on 
the micro and macro nutrients present in Moringa was performed by I. J. Asiedu-Gyekye 
and colleagues using an in vivo murine model [80]. In their studies to access the 
macromolecules, they treated mice with a subacute single dose of 5000 mg/ kg and a range 
of 0 mg/kg to 1000/kg (40, 80, 200, and 1000 mg/kg) for 14 days. White blood cell counts 
increased by 52.5% compared to controls in their single high dose as well as in their 
40mg/kg and 80 mg/kg dosages [80].  
In comparison, we performed our studies at 30 mg/g (low dose) and 60mg/g (high 
dose) and only treated for 7 days or 9 days, compared to 14 days by the other researchers. 
We believe that immune suppression may occur early in Moringa treatment at suboptimal 
levels (as our results show), but when treated for longer periods of time at a dosage of 
40mg/kg to approximately 80mg/kg there is immune stimulation as shown by I. J. Asiedu-
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Gyekye.  It is also possible that the content of macromolecules may be higher as we used 
already processed Moringa from a commercial vendor. Overall, our data, along with the 
results shown by I. J. Asiedu-Gyekye [80], lead us to believe that there is a delicate balance 
between the immune system and Moringa dosage that must be maintained to improve the 
benefits from Moringa’s documented immune stimulating and anti-plasmodial properties.  
These immune stimulating properties prompted us to determine if prophylactic and 
curative treatments would stimulate the generation of effector memory and central memory 
CD4+ T cells. Since both P. falciparum and P. chabaudi cause a chronic infection, research 
has shown that these memory T cell subsets are necessary for protection against severe 
malaria as the infection persists over a long time [81,82]. Central memory T cells are 
thought to regenerate more of the functional effector memory subsets [24,83]. We observed 
that both long term low and high dose curative Moringa treatment reduced the proportion 
of Tem. In both studies we also observed an increase in Tcm cells in mice treated 
prophylactically. This was accompanied by a reduction in the proportions of IFN and a 
trend towards reduced TNF (Figure 7&8) This was not surprising as there are less 
parasites at day 60, hence less proinflammatory cytokines produced.  As CD4+ T cells 
persist in chronic infection, this may induce inflammation. Therefore, we sought to 
determine levels of IL-2 which promotes T cell proliferation and IL-10 which has been 
shown to down regulate the effects of inflammation in chronic infections [69].  We 
observed increased IL-2 and a trend towards increased IL-10 in the mice fed 
prophylactically (Figure 8). This suggests that Moringa not only increases Teff numbers 
and proportions early but also stimulates the production of central memory CD4+ T cells 
which could be beneficial in subsequent Plasmodium infections. 
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In our second aim we assessed the contribution of malnutrition by food limitation 
and malaria immunity to mimic field scenarios and determined how Moringa could 
contribute to alleviating these defects. It has been shown that children who are 
malnourished suffer more clinical episodes of malaria with greater morbidity [63]. Given 
that Moringa is commonly consumed as a protein supplement in areas where malnutrition 
is prevalent [84], we investigated its effect on food limitation induced malnutrition. Many 
rural areas suffer from malnutrition and lack of access to basic health services [85]. We 
observed that malnourished mice exhibited reduced Teff proportions and numbers 
accompanied by a slight reduction in TNF. We did not observe any difference in IFN 
expression of Tbet in the food limited mice. As B cells produce antibodies to protect against 
malaria, we determined the activation of B cells, as they are reliant on CD4+ T cells to 
perform their function [12]. There was a reduction in the number of activated B cells (data 
not shown). We theorize that without proper nutrition the immune system is suppressed 
leading to reduced Teff cells which results in reduced pro-inflammatory cytokine secretion. 
This would explain the slightly reduced TNF proportions compared to the control mice. 
We believe that Tbet is highly expressed as the immune system tries to compensate for the 
generation of Teff to control the infection (Figure 9).  
While malnutrition reduced Teff cells, we observed no difference in Tem or Tcm 
proportions or numbers. There was a reduction in TNF, but not IFN, similar to the effects 
observed in the Teff at day 9 post infection. As there was no increase in inflammatory 
cytokines, there was no significant difference in IL-10 production, but IL-2 was slightly 
reduced (Figure 10).  To assess the contribution of Moringa in alleviating the decreased 
immunity induced by malaria in malnourished mice, we supplemented a group of 
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malnourished mice with Moringa when food was removed. We observed that Moringa 
supplementation increased T cell proportions compared to the malnourished mice without 
supplementation as well as increased IL-10 expression compared to the malnourished 
group. There was also a reduction in IFN expression compared to the controls (Figure 
11). 
All these data together suggest that Moringa treatment improves the immune 
response and remediates immune suppression by malnutrition in P. chabaudi infected 
mice. We believe Moringa does this by both acting on the parasite directly , thereby 
reducing parasite burden, and activating the immune system. We believe this immune 
stimulation occurs by activation of Tbet and secretion of IL-2 which promotes the 
differentiation of Th1 cells into Teff. An increase in these cells increases IFN and TNF 
production leading to greater parasite control. We observed immune suppression in 
malnourished mice by a reduction in Teff cells leading to an increase in Tbet expression in 
this group. We observed that malnourished mice that were supplemented with nutritional 
Moringa exhibited increased Teff proportions and trends towards increased IL-2, and IL-
10 expression. This suggests that Moringa supplementation ameliorates the immune 
suppression induced by malnutrition as this group exhibits a phenotype similar to control 
mice. Overall, we believe that Moringa may be useful as an adjunct in the treatment of 
malaria as well as a nutritional supplement in malnourished populations.  
 
 
 
 
40 
 
 
Chapter 5 
CONCLUSIONS 
 
While Moringa is extensively believed to have anti-plasmodial properties by 
inhibiting parasite growth, our data suggest that it may enhance CD4+ T cell activation as 
well. Increased T cell numbers are important for helper function and parasite clearance by 
the host’s immune system. We observed decreased parasitemia in Moringa treated mice 
which was accompanied by increased cytokine secretion and Tbet expression in mice that 
were treated with Moringa before (prophylactic) or after (curative) infection. We also 
observed that this increases Tcm in prophylactically treated mice at both high and low 
doses. Moringa remediates the immune suppressing effects of food limitation induced 
malnutrition by increasing Teff proportions and IL-10 expression. We propose that use of 
Moringa prophylactically or curatively is beneficial in the control of malaria disease and 
may aid in the treatment of malnutrition and malaria infection.  
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